VisAcT (18F-AraG) for Cardiac Imaging

About CellSight Technologies

CellSight Technologies is a private, pre-revenue biotech focused on a diagnostic imaging platform for the immune system. Its core technology, the VisAcT (18F-AraG) PET tracer, selectively accumulates in activated T cells, providing a non-invasive window into immune activity. The company is actively advancing its platform through multiple investigator-sponsored clinical trials, primarily in non-small cell lung cancer (NSCLC), with the goal of guiding and improving immunotherapy outcomes. Its long-term vision extends to neurodegenerative and cardiac diseases where immune activation plays a key role.

Therapeutic Areas